GlassScriptPhysician profile
Lora J Shehi
NPI 1861451593
$5,432.60
in general payments reported to CMS, 2019-2025
39 companies · $1,185 in 2025
The $1,185 reported for 2025 was more than what 89% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $191 · 2021: $809 · 2022: $714 · 2023: $1,027 · 2024: $963 · 2025: $1,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,175.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $610.96 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $574.07 | 2021-2025 | Enhertu, Imfinzi, Lynparza |
| Daiichi Sankyo INC. | $503.77 | 2021-2025 | Enhertu |
| Lilly USA, LLC | $391.35 | 2020-2025 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $305.90 | 2021-2023 | Adcetris, Tukysa, Padcev |
| Merck Sharp & Dohme LLC | $299.86 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $291.23 | 2019-2023 | Lumakras |
| Incyte Corporation | $270.43 | 2021-2025 | Jakafi, Pemazyre, Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $212.87 | 2019-2025 | Iclusig, Ninlaro, Fruzaqla |
| Glaxosmithkline, LLC. | $153.44 | 2022-2024 | Zejula, Jemperli, Ojjaara |
| E.R. Squibb & Sons, L.L.C. | $149.91 | 2021-2024 | |
| Astellas Pharma US INC | $142.93 | 2020-2025 | Vyloy |
| Celgene Corporation | $128.40 | 2019-2020 | |
| Janssen Biotech, INC. | $127.93 | 2025 | Darzalex, Balversa, Erleada |
| Novo Nordisk INC | $125.00 | 2019 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lora Shehi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.